Anti-angiogenic effects of mammalian target of rapamycin inhibitors in a mouse model of oxygen-induced retinopathy

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 11, 2014, Pages 1838-1842

  Yagasaki, Rina ^a   Nakahara, Tsutomu ^a   Ushikubo, Hiroko ^a   Mori, Asami ^a   Sakamoto, Kenji ^a   Ishii, Kunio ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Mammalian target of rapamycin; Pathologic angiogenesis; Retina; Vascular endothelial growth factor

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; RAPAMYCIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MTOR PROTEIN, MOUSE; OXYGEN; S6 KINASE; TARGET OF RAPAMYCIN KINASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; OXYGEN-INDUCED RETINOPATHY; PROTEIN PHOSPHORYLATION; RETINA; RETINA NEOVASCULARIZATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PATHOLOGY; RETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; MICE, INBRED ICR; OXYGEN; RETINA; RETINAL NEOVASCULARIZATION; RIBOSOMAL PROTEIN S6 KINASES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84910070260     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00487     Document Type: Article

References (22)

1. Saint-Geniez M, D'Amore PA. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int. J. Dev. Biol., 48, 1045-1058 (2004).
2. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med., 1, 1024-1028 (1995).
3. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med., 351, 2805-2816 (2004).
4. Moradian S, Ahmadieh H, Malihi M, Soheilian M, Dehghan MH, Azarmina M. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol., 246, 1699-1705 (2008).
5. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N. Engl. J. Med., 364, 603-615 (2011).
6. Finger RP, Guymer RH, Gillies MC, Keeffe JE. The impact of antivascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. Ophthalmology, 121, 1246-1251 (2014).
7. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol., 22, 7004-7014 (2002).
8. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood, 100, 3767-3775 (2002).
9. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med., 8, 128-135 (2002).
10. Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, Lin MI, Walsh K, Dvorak AM, Briscoe DM, Neeman M, Sessa WC, Dvorak HF, Benjamin LE. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell, 10, 159-170 (2006).
11. Stahl A, Paschek L, Martin G, Gross NJ, Feltgen N, Hansen LL, Agostini HT. Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett., 582, 3097-3102 (2008).
12. Xue Q, Nagy JA, Manseau EJ, Phung TL, Dvorak HF, Benjamin LE. Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arterioscler. Thromb. Vasc. Biol., 29, 1172-1178 (2009).
13. Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol. Vis., 10, 964-972 (2004).
14. Shi W, Gao H, Xie L, Wang S. Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest. Ophthalmol. Vis. Sci., 47, 3339-3344 (2006).
15. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci., 35, 101-111 (1994).
16. Morita A, Nakahara T, Abe N, Kurauchi Y, Mori A, Sakamoto K, Nagamitsu T, Ishii K. Effects of pre- and post-natal treatment with KRN633, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on retinal vascular development and patterning in mice. Exp. Eye Res., 120, 127-137 (2014).
17. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. U.S.A., 92, 905-909 (1995).
18. Kasai A, Shintani N, Kato H, Matsuda S, Gomi F, Haba R, Hashimoto H, Kakuda M, Tano Y, Baba A. Retardation of retinal vascular development in apelin-deficient mice. Arterioscler. Thromb. Vasc. Biol., 28, 1717-1722 (2008).
19. del Toro R, Prahst C, Mathivet T, Siegfried G, Kaminker JS, Larrivee B, Breant C, Duarte A, Takakura N, Fukamizu A, Penninger J, Eichmann A. Identification and functional analysis of endothelial tip cell-enriched genes. Blood, 116, 4025-4033 (2010).
20. Kasai A, Ishimaru Y, Kinjo T, Satooka T, Matsumoto N, Yoshioka Y, Yamamuro A, Gomi F, Shintani N, Baba A, Maeda S. Apelin is a crucial factor for hypoxia-induced retinal angiogenesis. Arterioscler. Thromb. Vasc. Biol., 30, 2182-2187 (2010).
21. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol., 171, 53-67 (2007).
22. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA. Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS ONE, 3, e3554 (2008).